生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Vicriviroc maleate is a CCR5 antagonist with IC50 of 0.91 nM in clinical development for the treatment of HIV-1. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00551330 | HIV Infections ... 展开 >> Acquired Immunodeficiency Syndrome 收起 << | Phase 2 | Completed | - | - |
NCT00705419 | - | Completed | - | - | |
NCT00243230 | HIV Infections | Phase 2 | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.54mL 0.31mL 0.15mL |
7.70mL 1.54mL 0.77mL |
15.39mL 3.08mL 1.54mL |
参考文献 |
---|